Association of germline variants with KRAS-mutation status in colorectal cancer

Read full text
Authors: Nijole Pollock Tjader, Johnny R. Ramroop, Tanish Gandhi, Cara Dauch, Owen Meadows, Patrick Stevens, Rachel Pearlman, Heather L. Hampel, Elom Kouassivi Aglago, Sonja I. Berndt, Amanda M. Bloomer, Hermann Brenner
+44 more Daniel D. Buchanan, Peter T. Campbell, Yin Cao, Andrew Tan Chan, Iona C. Cheng, Niki L. Dimou, David A. Drew, Amy J. French, Peter Georgeson, Marios Giannakis, Graham G. Giles, Maria Gomez, Stephen B. Gruber, Michael Hoffmeister, Wen-Yi Huang, Meredith A.J. Hullar, Jeroen R. Huyghe, Nicole Catalina Lorona, Victor Rau Moreno, Christina C. Newton, Jonathan Andrew Nowak, Mireia Obón‐Santacana, Shuji Ogino, Andrew Jared Pellatt, Anita Roselyn Peoples, Jennifer B. Permuth, Stephanie L. Schmit, RE Schoen, Erin M. Siegel, Robert S. Steinfelder, Wei Sun, Jamie K. Teer, Claire Elizabeth Thomas, Quang M. Trinh, Konstantinos K. Tsilidis, Tomotaka Ugai, Caroline Y. Um, Bethany R. Van Guelpen, Syed H. Zaidi, Jane Figueiredo, Ulrike Peters, Amanda I. Phipps, Joseph Paul McElroy, Amanda Ewart Toland
Cited by: 0
References: 50

Abstract

Somatic mutations in KRAS are a common driver of colorectal cancer (CRC) and present at different frequencies by race, sex, tumor site, ethnicity, and genetic similarity. Inherited germline variants may influence tumor somatic mutation frequency by altering mutation or DNA repair processes or altering cellular, immunological and/or microenvironmental responses after a mutation. We hypothesized that the germline genetic background modifies somatic KRAS mutation frequency in CRC. To test this, we performed a genome-wide association study (GWAS) in 7071 individuals with CRC, using KRAS mutation status as the phenotype. Single-nucleotide variants were chosen for validation analyses based on P values from the discovery GWAS, predicted in silico functional effects, and proximity to genes with potential cancer relevance. A validation analysis of 101 SNVs of interest was performed in 2482 individuals. No SNVs were significantly associated with KRAS -mutant CRC ( P value < 0.0005). One variant rs73067863-T showed a non-significant exploratory association with fewer KRAS -mutant tumors in the combined sample ( P value = 9.7 × 10 –7 , OR = 0.75). Follow-up studies are needed to determine if these or other germline variants impact population differences in KRAS mutations in CRC.

Fields of Study & Subjects

Genetic factors in colorectal cancer Genetic Associations and Epidemiology Colorectal Cancer Treatments and Studies

Publication details

Journal / source
Scientific Reports
Volume
16
Issue
1
Publication date
13 February 2026
Language
EN